Leerink Partnrs Has Positive Forecast for Xencor Q3 Earnings

Xencor, Inc. (NASDAQ:XNCR) – Analysts at Leerink Partnrs increased their Q3 2025 EPS estimates for shares of Xencor in a report released on Wednesday, August 6th. Leerink Partnrs analyst J. Chang now expects that the biopharmaceutical company will post earnings of ($0.74) per share for the quarter, up from their prior estimate of ($0.76). The consensus estimate for Xencor’s current full-year earnings is ($3.68) per share. Leerink Partnrs also issued estimates for Xencor’s Q4 2025 earnings at ($0.95) EPS, FY2025 earnings at ($2.76) EPS and FY2026 earnings at ($3.18) EPS.

Several other analysts have also commented on XNCR. Barclays cut their target price on shares of Xencor from $22.00 to $6.00 and set an “underweight” rating for the company in a research note on Thursday, May 8th. William Blair initiated coverage on shares of Xencor in a research note on Monday, April 21st. They set an “outperform” rating for the company. Wedbush cut their target price on shares of Xencor from $31.00 to $26.00 and set an “outperform” rating for the company in a research note on Thursday, August 7th. Finally, Wells Fargo & Company cut their target price on shares of Xencor from $33.00 to $27.00 and set an “overweight” rating for the company in a research note on Thursday, August 7th. Two research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $26.43.

Xencor Price Performance

XNCR stock opened at $7.00 on Monday. Xencor has a 12 month low of $6.92 and a 12 month high of $27.24. The firm has a market cap of $499.24 million, a PE ratio of -2.92 and a beta of 0.89. The firm has a 50 day simple moving average of $8.64 and a 200 day simple moving average of $10.78.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.37. Xencor had a negative net margin of 121.52% and a negative return on equity of 25.75%. The company had revenue of $43.61 million for the quarter, compared to the consensus estimate of $22.59 million. During the same period in the previous year, the firm earned ($1.07) EPS. Xencor’s revenue was up 82.4% on a year-over-year basis.

Institutional Trading of Xencor

Several large investors have recently added to or reduced their stakes in the company. Primecap Management Co. CA raised its stake in Xencor by 7.9% during the 2nd quarter. Primecap Management Co. CA now owns 10,527,322 shares of the biopharmaceutical company’s stock valued at $82,745,000 after purchasing an additional 766,310 shares during the period. Creative Planning lifted its position in Xencor by 25.3% in the 2nd quarter. Creative Planning now owns 18,130 shares of the biopharmaceutical company’s stock worth $143,000 after buying an additional 3,661 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its position in Xencor by 9.1% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 18,272 shares of the biopharmaceutical company’s stock worth $144,000 after buying an additional 1,525 shares in the last quarter. Police & Firemen s Retirement System of New Jersey lifted its position in Xencor by 16.1% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 16,470 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 2,281 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in Xencor by 1.8% in the 2nd quarter. Geode Capital Management LLC now owns 1,703,664 shares of the biopharmaceutical company’s stock worth $13,393,000 after buying an additional 29,316 shares in the last quarter.

Insider Buying and Selling at Xencor

In other Xencor news, Director Kurt A. Gustafson sold 2,993 shares of the business’s stock in a transaction on Monday, June 16th. The shares were sold at an average price of $9.22, for a total transaction of $27,595.46. Following the sale, the director directly owned 20,183 shares of the company’s stock, valued at $186,087.26. The trade was a 12.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ellen Feigal sold 2,993 shares of the business’s stock in a transaction on Monday, June 16th. The shares were sold at an average price of $9.22, for a total transaction of $27,595.46. Following the sale, the director directly owned 19,183 shares in the company, valued at approximately $176,867.26. This trade represents a 13.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 11,194 shares of company stock valued at $103,209 in the last three months. 5.23% of the stock is currently owned by company insiders.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.